Asia-Pacific monoclonal antibodies market is estimated to grow at a CAGR of 8.9% during the forecast period. Significant rise in the incidences of cancer and infectious diseases and increasing approvals of biosimilars are primarily encouraging the market growth. The rising number of approvals for monoclonal antibodies biosimilars has been reported in the region owing to the increasing government focus towards improving access to care for patients. For instance, in October 2020, Cadila Pharmaceuticals introduced two similar biologics in the Indian market. This includes Cadalimab, a similar biologic of the auto-immune treatment adalimumab, and NuPTH, a teriparatide similar biologic. Cadila has revealed four new products in India since July 2020.
Get Free Sample link @ https://www.omrglobal.com/request-sample/asia-pacific-monoclonal-antibodies-market
Adalimumab is a monoclonal antibody therapy for inflammatory diseases which include several types of arthritis, psoriasis, and inflammatory bowel disease (IBD). Adalimumab was the first human monoclonal antibody treatment approved by the US FDA which is sold with the brand name Humira since 2003. A biosimilar of adalimumab is sold as Cadalimab which is available in a form of a pre-filled syringe to facilitate ease of use. This biosimilar has been demonstrated to be effective to treat rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, psoriasis, and ankylosing spondylitis. It is available in a 40 mg/0.8 mL injectable dose. The increasing launches of biosimilars are offering hope for patients with cancer, auto-immune diseases, infectious diseases, and others, to receive affordable treatment. This, in turn, is providing an enormous scope for market growth.
A full report of Asia-Pacific Monoclonal Antibodies Market available @ https://www.omrglobal.com/industry-reports/asia-pacific-monoclonal-antibodies-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Asia-Pacific Monoclonal Antibodies Market by Source
- Murine
- Chimeric
- Human
- Humanized
Asia-Pacific Monoclonal Antibodies Market by Application
- Cancer
- Infectious Diseases
- Auto-Immune Diseases
- Inflammatory Diseases
- Others
Regional Analysis
- China
- India
- Japan
- Rest of Asia-Pacific
Company Profiles
- Amgen Inc.
- Anhui Anke Biotechnology (Group) Co., Ltd.
- Biocon Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Ltd.
- Reddy’s Laboratories, Inc.
- GenorBioPharma Co., Ltd.
- Lupin Ltd.
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
The Report Covers
- Comprehensive research methodology of the Asia-Pacific monoclonal antibodies market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Asia-Pacific monoclonal antibodies market.
- Insights about market determinants which are stimulating the Asia-Pacific monoclonal antibodies market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
